Stridebio
Durham, US · Founded 2015 · Delaware corporation · 2 known investors
StrideBio develops gene therapies based on its STRIVE AAV capsid platform, targeting people with life-threatening diseases. The company focuses on drug development and AAV manufacturing in the gene therapy field.
Founders & leadership
Stridebio was founded in 2015 by Aravind Asokan and Mavis Abjandje-McKenna.
AA
Aravind AsokanCo-founder
MA
Mavis Abjandje-McKennaCo-founder
RS
Richard SmithExecutive
PR
Patrick RitschelNamed on SEC filing
Investors · 2
Reported raises · per SEC filings
Form D private placements$57.7M disclosed across 3 rounds · 2017–2021
▶$48.9MraisedMar 2021 · 17 investors · BiotechnologyRule 506(b)
▶$48.9MraisedMar 2021 · 17 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Sapan ShahExecutive Officer, Director
- Maritza McIntyreExecutive Officer
- William MonteithExecutive Officer
- Robert HughesExecutive Officer
- Shaan GandhiDirector
- Stewart ParkerDirector
- Clay ThorpDirector
- Erica WhittakerDirector
- Michael MartinDirector
- Aravind AsokanDirector
- Karen HongDirector
- Offering amount
- $81.5M
- Amount sold
- $48.9M
- First sale
- Mar 2021
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$7.7MraisedJun 2018 · 12 investors · BiotechnologyRule 506(b)
▶$7.7MraisedJun 2018 · 12 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Clay ThorpDirector
- Stewart ParkerDirector
- Mike DialDirector
- Mavis Agbandje-McKennaDirector, Promoter
- Aravind AsokanDirector, Promoter
- Patrick RitschelExecutive Officer, Director, Promoter
- Richard SmithExecutive Officer
- Offering amount
- $15.8M
- Amount sold
- $7.7M
- First sale
- Jun 2018
- Incorporated
- Corporation, Delaware, 2015
- Federal exemptions
- 06b
▶$1MraisedJun 2017 · 3 investors · BiotechnologyRule 506(c)
▶$1MraisedJun 2017 · 3 investors · Biotechnology
Rule 506(c)Officers, directors & promoters on the filing
- Richard SmithExecutive Officer
- Aravind AsokanDirector
- Patrick RitschelExecutive Officer, Director, Promoter
- Mavis Abjandje-McKennaDirector
- Offering amount
- $1M
- Amount sold
- $1M
- Minimum investment
- $90K
- First sale
- May 2017
- Incorporated
- Corporation, Delaware, 2015
- Federal exemptions
- 06c
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 6
by search overlap
Bridgebio8 shared keywordsBridgeBio develops treatments for genetic conditions and cancers using a decentralized hub-and-spoke model, where autonomous teams focus on specific diseases or drug candidates while a central hub provides clinical, regulatory, and commercial support. The company partners with academic institutions to advance early-stage research toward late-stage clinical trials.
Dispatch Biotherapeutics7 shared keywordsDispatch Bio develops a universal immunotherapy treatment for solid tumors, combining engineered immunotherapy with a tumor-specific virus to improve cancer treatment outcomes.
Treeline Biosciences5 shared keywordsTreeline develops therapeutics focused on oncology, leveraging insights from clinical practice and laboratory research. The company serves cancer patients through drug discovery and development.
Formation Bio5 shared keywordsFormation Bio develops drugs through partnerships with health systems, academic medical centers, and research sites, focusing on clinical trials in dermatology, rheumatology, and cardiometabolic diseases. The company provides trial management infrastructure, monitoring, technology, and enrollment support to accelerate drug development.
GentiBio5 shared keywordsGentiBio develops engineered regulatory T-cell (EngTreg) therapies designed to reset the immune system and treat autoimmune and acute inflammatory diseases. The company builds autologous and allogeneic Treg platforms as an alternative to systemic immune-suppressive therapies.
Precision BioSciences4 shared keywordsPrecision BioSciences develops gene-editing medicines using its proprietary ARCUS genome editing platform, which employs sequence-specific nuclease enzymes to insert, remove, or repair DNA in living cells to treat hard-to-treat conditions including rare genetic diseases and hepatitis B (HBV).
Companies competing with Stridebio for the same Google search keywords, organic and paid, via search-intersection analysis.
Frequently asked questions
- What does Stridebio do?
- StrideBio develops gene therapies based on its STRIVE AAV capsid platform, targeting people with life-threatening diseases. The company focuses on drug development and AAV manufacturing in the gene therapy field.
- Who founded Stridebio?
- Stridebio was founded by Aravind Asokan, Mavis Abjandje-McKenna in 2015.
- Who are Stridebio's investors?
- Stridebio's investors include Pontifax Venture Capital, Hatteras Venture Partners.
- How much funding has Stridebio raised?
- Stridebio has disclosed $57.7M raised across 3 rounds.
- Where is Stridebio headquartered?
- Stridebio is headquartered in Durham, US.